Dyne Therapeutics (NASDAQ:DYN) Director Brian Posner Buys 2,500 Shares

Posted by Brenda Bartman on Jun 5th, 2026

Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) Director Brian Posner bought 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was purchased at an average price of $17.48 per share, for a total transaction of $43,700.00. Following the completion of the transaction, the director directly owned 22,500 shares of the company’s stock, valued at $393,300. This represents a 12.50% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website.

Dyne Therapeutics Price Performance

Shares of NASDAQ:DYN traded down $1.37 during mid-day trading on Friday, reaching $17.04. The stock had a trading volume of 1,882,492 shares, compared to its average volume of 1,967,476. The company has a current ratio of 19.92, a quick ratio of 19.92 and a debt-to-equity ratio of 0.17. The company has a market cap of $2.82 billion, a P/E ratio of -5.29 and a beta of 1.09. Dyne Therapeutics, Inc. has a 1 year low of $8.06 and a 1 year high of $25.00. The business’s 50 day moving average price is $18.32 and its 200 day moving average price is $18.29.

Dyne Therapeutics (NASDAQ:DYN – Get Free Report) last posted its earnings results on Monday, May 11th. The company reported ($0.73) EPS for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.04. During the same period in the previous year, the company earned ($1.05) earnings per share. Research analysts expect that Dyne Therapeutics, Inc. will post -3 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Sanford C. Bernstein boosted their price objective on Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a research note on Wednesday, May 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Monday, April 20th. Evercore set a $33.00 price objective on Dyne Therapeutics in a research note on Friday, May 15th. Jefferies Financial Group reissued a “buy” rating on shares of Dyne Therapeutics in a research note on Monday, March 9th. Finally, Morgan Stanley reduced their price objective on Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating on the stock in a research note on Monday, March 2nd. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Dyne Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $35.00.

View Our Latest Analysis on Dyne Therapeutics

Institutional Investors Weigh In On Dyne Therapeutics

Several large investors have recently added to or reduced their stakes in DYN. JPMorgan Chase & Co. grew its stake in shares of Dyne Therapeutics by 9.0% during the third quarter. JPMorgan Chase & Co. now owns 3,365,245 shares of the company’s stock valued at $42,570,000 after buying an additional 278,466 shares during the last quarter. Aberdeen Group plc grew its stake in shares of Dyne Therapeutics by 15.0% during the third quarter. Aberdeen Group plc now owns 556,733 shares of the company’s stock valued at $7,043,000 after buying an additional 72,770 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Dyne Therapeutics by 27.6% during the third quarter. Vanguard Group Inc. now owns 9,760,414 shares of the company’s stock valued at $123,469,000 after buying an additional 2,109,257 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of Dyne Therapeutics during the fourth quarter valued at approximately $5,191,000. Finally, Rafferty Asset Management LLC grew its stake in shares of Dyne Therapeutics by 93.4% during the third quarter. Rafferty Asset Management LLC now owns 213,211 shares of the company’s stock valued at $2,697,000 after buying an additional 102,963 shares during the last quarter. 96.68% of the stock is owned by institutional investors.

About Dyne Therapeutics

(Get Free Report)

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.